Tech Company Financing Transactions
Atritech Funding Round
Atritech, based in Plymouth, secured $22 million in investment from SightLine Partners and Prism VentureWorks.
Transaction Overview
Company Name
Announced On
9/5/2007
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Undisclosed
Investors
SightLine Partners (Lead Investor) (Buzz Benson)
Prism VentureWorks (Gordie Nye)
Proceeds Purpose
With this new funding, the Company will complete the enrollment phase
of its PROTECT AF clinical trial along with the preparation and submission
of clinical results to the FDA. The PROTECT AF clinical trial is evaluating
the WATCHMAN(R) device versus the current standard of care, Coumadin, in
patients with AF. The PROTECT AF clinical trial is being conducted in 60
sites across the United States and Europe and is in the final stage of
enrollment with approximately 600 patients enrolled, of which 300 patients
have been enrolled since the beginning of the year.
Company Information
Company Status
Acquired or Merged
Industry
Medical Devices & Instruments
Mailing Address
3750 Annapolis Ln. 105
Plymouth, MN 55447
USA
Plymouth, MN 55447
USA
Phone
Website
Email Address
Overview
Atritech is an emerging medical device company focused on preventing atrial fibrillation (AF) related stroke through technology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jim Bullock
VP - Finance
Brad Swatfager
VP - Marketing
Maggie Wallner
VP - Operations
Mike Costello
Browse more venture capital transactions:
Prev: 9/5/2007: SAY Media venture capital transaction
Next: 9/5/2007: Atempo venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to record all VC transactions involving tech companies. All VC database entries reported here come from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs